Biodexa Pharmaceticals Total Assets
Biodexa Pharmaceticals total assets. Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) holds total assets worth $18.15 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Biodexa Pharmaceticals worth for the company's overall valuation and market capitalisation.
Total Assets of Biodexa Pharmaceticals (2012–2025)
Total assets of Biodexa Pharmaceticals from 2012 to 2025. This chart illustrates how Biodexa Pharmaceticals's total assets have evolved over time, based on quarterly financial data. See BDRX live share price for real-time trading data and today's change.
Biodexa Pharmaceticals - Asset Composition Analysis
Biodexa Pharmaceticals Total Assets Breakdown (December 2025)
Biodexa Pharmaceticals total assets breakdown as of December 2025. Biodexa Pharmaceticals's total assets of $18.15 Million consist of 68.5% current assets and 31.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.9% |
| Accounts Receivable | $221.61K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.64 Million | 31.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BDRX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biodexa Pharmaceticals's current assets represent 68.5% of total assets in 2025, an increase from 49.4% in 2012.
- Cash Position: Cash and equivalents constituted 46.9% of total assets in 2025, up from 6.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.
Biodexa Pharmaceticals Competitors by Total Assets
Key competitors of Biodexa Pharmaceticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Biodexa Pharmaceticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.03 | 1.75 | 3.10 |
| Quick Ratio | 2.03 | 1.75 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.30 Million | $3.78 Million | $6.29 Million |
Biodexa Pharmaceticals - Advanced Valuation Insights
This section examines the relationship between Biodexa Pharmaceticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.18 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 22.8% |
| Total Assets | $18.15 Million |
| Market Capitalization | $1.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biodexa Pharmaceticals's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biodexa Pharmaceticals's assets grew by 22.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual total assets of Biodexa Pharmaceticals from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.15 Million | +22.78% |
| 2024-12-31 | $14.78 Million | +40.20% |
| 2023-12-31 | $10.54 Million | +90.81% |
| 2022-12-31 | $5.53 Million | -57.21% |
| 2021-12-31 | $12.91 Million | +31.54% |
| 2020-12-31 | $9.82 Million | -68.22% |
| 2019-12-31 | $30.89 Million | +51.12% |
| 2018-12-31 | $20.44 Million | -58.47% |
| 2017-12-31 | $49.22 Million | -13.17% |
| 2016-12-31 | $56.69 Million | -11.48% |
| 2015-12-31 | $64.04 Million | +37.24% |
| 2014-12-31 | $46.66 Million | +801.87% |
| 2013-12-31 | $5.17 Million | +43.31% |
| 2012-12-31 | $3.61 Million | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more